The messenger RNA drug developer, backed by Monsanto, Merck & Co, GlaxoSmithKline, Pfizer and Merck Group, has raised more than $121m in its initial public offering.

Johns Hopkins-backed biopharmaceutical developer Allakos has filed for a $75m initial public offering after raising more than $160m in equity funding.

UC Investment Office-backed gene expression technology developer Constellation Pharmaceuticals has filed for an $86.3m initial public offering.

SR One-backed gene expression technology developer Constellation Pharmaceuticals has filed for an $86.3m initial public offering.

Roche and Novo-backed biopharmaceutical developer Allakos has filed for a $75m initial public offering after raising more than $160m in equity funding.

The Merck GHI-backed medical device developer had raised $120m in funding prior to its initial public offering.

The online automotive retail platform is targeting $300m in an offering that will score exits for Tencent, Didi Chuxing and Taikang Life.

Onyx Therapeutics-backed autoimmune drug developer Kezar Life Sciences has closed its initial public offering at $86.3m.

The transplant-based medicine developer, backed by Alphabet, Partners Healthcare and Access Industries, floated in the middle of its range.

The local services platform, which counts Tencent as its largest investor, has filed for an offering that could net more than $4bn at a $60bn valuation.